-
Product Insights
Ocular Hypertension – Drugs In Development, 2023
Global Markets Direct’s, ‘Ocular Hypertension - Drugs In Development, 2023’, provides an overview of the Ocular Hypertension pipeline landscape. The report provides comprehensive information on the therapeutics under development for Ocular Hypertension, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Open-Angle Glaucoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Open-Angle Glaucoma - Drugs In Development, 2023’, provides an overview of the Open-Angle Glaucoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Open-Angle Glaucoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Macular Edema – Drugs In Development, 2023
Global Markets Direct’s, ‘Macular Edema - Drugs In Development, 2023’, provides an overview of the Macular Edema pipeline landscape. The report provides comprehensive information on the therapeutics under development for Macular Edema, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Glaucoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Glaucoma - Drugs In Development, 2023’, provides an overview of the Glaucoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Glaucoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Inborn Gene or Chromosome Alterations Pipeline by Development Stages, Segments, Countries, Regulatory Path and Key Companies
Inborn Gene or Chromosome Alterations Pipeline Product Market Overview The Inborn Gene or Chromosome Alterations pipeline market research report provides a comprehensive understanding of the pipeline products along with their comparative analysis at various stages of development. The report also includes information about the territories wherein the clinical trials are in progress, the regulatory paths followed by the trials, and the companies associated with the trials. Key Territories ·       The US ·       Europe ·       Canada ·       China ·       Australia Key...
-
Sector Analysis
Turkey Destination Tourism Trends Insight by Type, Source Markets, Foreign Direct Investment and Future Opportunities, 2023 Update
Turkey Destination Tourism Insight Report Overview The total number of inbound tourists in Turkey is expected to exceed 2019 levels in 2023 reaching 48.5 million with a projected CAGR of more than 7% between 2022 and 2027. Turkey is a country that is geographically distinct because it is divided between Asia and Europe. Even though most of its tourism still centers on historical monuments and beach resorts, the country is growing as a popular destination for medical treatment, cosmetic procedures,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Bevacizumab Biosimilar in Diabetic Macular Edema
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Bevacizumab Biosimilar in Diabetic Macular Edema report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Bevacizumab Biosimilar in Diabetic Macular EdemaDrug Details:PRO-169 (bevacizumab) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PIT-565 in B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PIT-565 in B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.PIT-565 in B-Cell Acute Lymphocytic Leukemia (B-Cell...